Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic LeukemiaJan A. Burger, Thomas J. Kipps, David Simpson et al.|New England Journal of Medicine|2015Cited by 1.6k
Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemiaDavide Rossi, Gianluca Gaïdano, Lodovico Terzi-di-Bergamo et al.|Blood|2015Cited by 215
Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter studyJorge J. Castillo, Steven P. Treon, Gilad Itchaki et al.|Blood|2018Cited by 100
Using Ibrutinib in Earlier Lines of Treatment Results in Better Outcomes for Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaPaul M. Barr, Susan O’Brien, Alessandra Tedeschi et al.|Blood|2019Cited by 2
Zanubrutinib for the treatment of patients with del(17p) and/or <i>TP53</i> CLL/SLL: analysis across clinical studiesConstantine S. Tam, Jennifer R. Brown, Mary Ann Anderson et al.|Blood Advances|2025Cited by 2